BETA-THALASSEMIA POTENCY ASSAY
Disclosed herein are potency assays for a gene therapy treatment for β-thalassemia. Also disclosed herein are methods for measuring relative potency of a drug product.
1 . A potency assay for a gene therapy treatment for β-thalassemia comprising:
a) transducing a sample of hematopoietic stem or progenitor cells from a subject having β-thalassemia with a lentiviral vector comprising a polynucleotide encoding a globin;
b) erythroid-differentiating the transduced hematopoietic stem or progenitor cells;
c) erythroid-differentiating a sample of untransduced hematopoietic stem or progenitor cells from the subject having β-thalassemia;
d) measuring fold change in Hemoglobin A expression in the transduced and the untransduced erythroid cell samples; and
e) measuring fold change in enucleated reticulocytes in the transduced and the untransduced erythroid cell samples,
wherein the potency of the gene therapy is assessed as the fold change in HbA expression and/or fold change in percent enucleated reticulocytes, in the transduced compared to the untransduced erythroid cell samples.
2 .- 3 . (canceled)
4 . The potency assay of claim 1 , further comprising obtaining the hematopoietic stem or progenitor cells from the subject that has β-thalassemia.
5 . The potency assay of claim 1 , wherein the hematopoietic stem or progenitor cells comprise CD34 + cells or CD133 + cells.
6 . (canceled)
7 . The potency assay of claim 1 , wherein the hematopoietic stem or progenitor cells comprise CD34 + CD38 Lo CD90 + CD45RA − cells.
8 . The potency assay of claim 1 , wherein the hematopoietic stem or progenitor cells comprise a pair of β-globin alleles selected from the group consisting of: β E /β 0 , β C /β 0 , β 0 /β 0 , β C /β C , β E /β E , β E /β + , β C /β E , β C /β + , β 0 /β + , and β + /β + .
9 . The potency assay of claim 1 , wherein the globin is a human β-globin, an anti-sickling globin, a human β A-T87Q -globin, a human β A-G16D/E22A/T87Q -globin, or a human β A-T87Q/K95E/K120E -globin protein.
10 . The potency assay of claim 1 , wherein the lentiviral vector is an AnkT9W vector, a T9Ank2W vector, a TNS9 vector, a TNS9.3 vector, a TNS9.3.55 vector, a lentiglobin HPV569 vector, a lentiglobin BB305 vector, a BG-1 vector, a BGM-1 vector, a GLOBE vector, a G-GLOBE vector, a βAS3-FB vector, or a derivative thereof.
11 . The potency assay of claim 1 , wherein the erythroid differentiation method comprises a two-stage culture.
12 . The potency assay of claim 1 , wherein the erythroid differentiation method occurs for a period of 14-18 days or for a period of 14-17 days.
13 . (canceled)
14 . The potency assay of claim 1 , wherein the fold change in Hemoglobin A expression is measured using ion-exchange HPLC.
15 . The potency assay of claim 1 , wherein the fold change in enucleated reticulocytes is measured using FACS.
16 . A method for measuring relative potency of a drug product comprising:
a) transducing a sample of hematopoietic stem or progenitor cells from the subject having β-thalassemia with a lentiviral vector comprising a polynucleotide encoding a globin and erythroid differentiating the transduced cells;
b) erythroid differentiating a sample of untransduced hematopoietic stem or progenitor cells from the subject having β-thalassemia;
c) quantifying fold change in Hemoglobin A (HbA) expression in the transduced erythroid cells compared to the HbA expression in the untransduced erythroid cells; and
d) quantifying fold change in the number of enucleated reticulocytes in the transduced erythroid cells compared to the number of enucleated reticulocytes in the untransduced cells,
wherein the transduced erythroid cells contain the lentiviral vector comprising the polynucleotide encoding a globin.
17 .- 18 . (canceled)
19 . The method of claim 16 , further comprising obtaining the hematopoietic stem or progenitor cells from the patient having β-thalassemia.
20 . The method of claim 16 , wherein the hematopoietic stem or progenitor cells comprise CD34 + cells or CD133 + cells.
21 . (canceled)
22 . The method of claim 16 , wherein the hematopoietic stem or progenitor cells comprise CD34 + CD38 Lo CD90 + CD45RA − cells.
23 . The method of claim 16 , wherein the hematopoietic stem or progenitor cells comprise a pair of β-globin alleles selected from the group consisting of: β E /β 0 , β C /β 0 , β 0 /β 0 , β C /β C , β E /β E , β E /β + , β C /β E , β C /β + , β 0 /β + , and β + /β + .
24 . The method of claim 16 , wherein the globin is a human β-globin, an anti-sickling globin, a human β A-T817Q -globin, a human β A-G16D/E22A/T87Q -globin, or a human β A-T87Q/K95E/K120E -globin protein.
25 . The method of claim 16 , wherein the lentiviral vector is an AnkT9W vector, a T9Ank2W vector, a TNS9 vector, a TNS9.3 vector, a TNS9.3.55 vector, a lentiglobin HPV569 vector, a lentiglobin BB305 vector, a BG-1 vector, a BGM-1 vector, a GLOBE vector, a G-GLOBE vector, a βAS3-FB vector or a derivative thereof.
26 . The method of claim 16 , wherein the fold change in Hemoglobin A expression is measured using ion-exchange high-performance liquid chromatography (HPLC).
27 . The method of claim 16 , wherein the fold change in enucleated reticulocytes is measured using fluorescence-activated cell sorting (FACS).
28 . (canceled)
29 . The method of claim 16 , wherein the erythroid differentiation method comprises a two-stage culture.
30 . The method of claim 16 , wherein the erythroid differentiation method occurs for a period of 14-18 days or for a period of 14-17 days.